Analyst Whitney Ijem from Canaccord Genuity has maintained a Buy rating on Arcturus Therapeutics (ARCT) with a price target of $74.00. This recommendation comes amidst increasing concerns over H5N1, also known as bird flu, with confirmed human cases in the US on the rise. The situation underscores the urgent need for effective vaccines, positioning Arcturus Therapeutics' self-amplifying mRNA approach, particularly their ARCT-2304 vaccine, as a timely solution. The company has recently initiated a Phase 1 clinical trial for ARCT-2304, marking a strategic move in a promising market segment.
Current H5N1 treatment options and vaccines are deemed insufficient, as existing stocks do not effectively match the circulating strain. This gap highlights the potential of next-generation treatments like those being developed by Arcturus, offering a significant opportunity to address unmet needs in the vaccine landscape. Whitney Ijem's optimism about the company's growth prospects and innovative approach underpins the Buy recommendation.
Whitney Ijem, a 3-star analyst with an average return of 3.5% and a 45.81% success rate, covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Alnylam Pharma, and Vertex Pharmaceuticals. In a related development, H.C. Wainwright also maintained a Buy rating on Arcturus Therapeutics with a $63.00 price target.
Arcturus Therapeutics Holdings, Inc., founded in 2013 and headquartered in San Diego, CA, specializes in the development of RNA therapeutics for the treatment of liver and respiratory diseases. Its pipeline includes LUNAR-OTC and LUNAR CF.
